Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$11.75 USD
0.00 (0.00%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $11.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
PHAT 11.75 0.00(0.00%)
Will PHAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
3 Top Breakout Stocks Worth a Buy for Attractive Returns
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
Other News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
Phathom Pharmaceuticals’ Voquezna: A Buy Rating on Breakthrough GERD Treatment and Market Growth Potential
PHAT Stock Earnings: Phathom Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Phathom Pharmaceuticals Outperforms with Voquezna Driving Revenue Growth: Buy Rating Reaffirmed
Phathom Pharmaceuticals Non-GAAP EPS of -$1.25, revenue of $7.3M